bioRxivMolecular BiologyPreprint
The Wild-type and Gain-of-function Mutant p53 Enhance p300 Autoacetylation through Conformational Switching
Stephanie KaypeeiD, Raka Ghosh, Smitha Asoka Sahadevan, Shilpa PatiliD, Manidip Shasmal, Piya Ghosh, Neeladri Sekhar Roy, Jayati SenguptaiD, Siddhartha RoyiD, Tapas Kumar KunduiD
Abstract
The transcriptional coactivator p300 is essential for p53 transactivation, although its precise mechanism remains unclear. We report that, p53 allosterically activates the acetyltransferase activity of p300 through the enhancement of p300 autoacetylation. Cryo-electron microscopy revealed that the domain organization of p300 is substantially altered upon binding of p53, suggesting that a structural switch may underpin the activation. Acetylated p300 accumulates near the transcription start sites accompanied by a similar enrichment of activating histone marks near those sites. Disruption of p53-p300 interaction by a site-directed peptide inhibitor abolished autoacetylated p300-mediated enhanced histone acetylation, suggesting a crucial role played by the allosteric activation in p53-mediated gene regulation. Gain-of-function mutant p53, known to impart aggressive proliferative properties in tumor cells, also activate p300 autoacetylation. The same peptide abolished many of the gain-of-functions of mutant p53 as well. We conclude that allosteric activation of p300 by p53 underpins gene regulation by p53. Reversal of gain-of-function properties of mutant p53 suggests that molecules targeting the p53-p300 interface may be good candidates for anti-tumor drugs.
- organism: human
- assay: protein structure
- research focus: protein structure prediction
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural insights into p300 regulation and acetylation-dependent genome organisation
Z. Ibrahim, T. Wang, … D. Panne·bioRxiv·Mar 14, 2022
- Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy
J. Zawacka-Pankau, V. V. Grinkevich, … G. Selivanova·bioRxiv·Dec 7, 2018
- p300 Is an Obligate Integrator of Combinatorial Transcription Factor Inputs
J. J. Ferrie, J. P. Karr, … X. Darzacq·bioRxiv·May 18, 2023
- Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency
M. Rigoli, G. Spagnolli, … A. Inga·bioRxiv·May 13, 2022
- Comparison of genotoxic vs. non-genotoxic stabilization of p53 provides insight into parallel stress-responsive transcriptional networks
Allison N. Catizone, Charly Ryan Good, … Morgan A. Sammons·Cell CyclePeer-reviewed·Apr 9, 2019
- P53 supresses transcription of the p300-E2F1-dependent gene subset by maintaining KDM5B associated with gene promoters
Karolina Gronkowska, Kinga Kołacz-Milewska, … Agnieszka Robaszkiewicz·bioRxiv·Aug 25, 2025